secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-016039
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q2 revenue $30M (+45% YoY); raises FY22 guidance to $130-134M; net loss widens to $17.2M
--------------------------------------------------------------------------------

- Revenue $30M, +45% YoY; gross margin 81.1% (+20 bps). Direct channel 68% of sales vs 51% prior year.
- Net loss attributable to common $17.2M ($0.31/share) vs $5.1M loss prior year; adjusted net loss $12.8M ($0.23/share).
- Adjusted EBITDA loss $9.4M vs $3.1M loss prior year; operating expenses increased to $36.2M from $20.7M.
- Raises FY2022 revenue guidance to $130-134M (38-42% growth) from prior $128-133M.
- Ended Q2 with $101.5M cash; new $150M loan arrangement provides liquidity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022016039/0000950170-22-016039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022016039/tmci-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer